XM does not provide services to residents of the United States of America.
B
B

Biomerieux

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Arkema, Flatexdegiro, Mediobanca

EUROPE RESEARCH ROUNDUP-Arkema, Flatexdegiro, Mediobanca Oct 31 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Arkema, Flatexdegiro and Mediobanca, on Thursday. HIGHLIGHTS * Arkema SA AKE.PA : Berenberg raises to buy from hold * Flatexdegiro AG FTKn.DE : Goldman Sachs raises to buy from neutral * Mediobanca MDBI.MI : Deutsche Bank raises to hold from sell * Orsted ORSTED.CO : Deutsche Bank cuts to hold from buy * Syensqo NV SYENS.
A
A
A
A
A
B
B
B
B
B
C
C
C
C
D
E
G
L
M
M
M
N
O
P
R
S
S
S
U
U
V
W
A
D
S
W

Biomerieux rises on Q3 sales growth above expectations

BUZZ-Biomerieux rises on Q3 sales growth above expectations ** Shares in Biomerieux BIOX.PA rise 3%, after it reports Q3 sales growth above expectations ** The french in-vitro diagnostic company released an 11% organic sales growth in the third quarter compared with the 8.4% expected in a consensus ** The group's growth was supported by a 17.6% gro
B

Biomerieux Q3 2024 +11% Organic Sales Growth At €969M

BRIEF-Biomerieux Q3 2024 +11% Organic Sales Growth At €969M Oct 30 (Reuters) - Biomerieux SA BIOX.PA : +11% ORGANIC SALES GROWTH IN Q3 2024 AT €969M CONFIRMATION OF THE 2024 FULL YEAR REVISED GUIDANCE FY OUTLOOK: CURRENCY EFFECT NEGATIVE IMPACT AROUND €60MLN ON ANNUAL CEBIT VERSUS AROUND €70M PREVIOUSLY Source text: [ https://tinyurl.com/4a
B

Ashmore, Biomerieux, Diasorin

EUROPE RESEARCH ROUNDUP-Ashmore, Biomerieux, Diasorin Oct 17 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Ashmore, Biomerieux and Diasorin, on Thursday. HIGHLIGHTS * Ashmore ASHM.L : JP Morgan raises target price to 161p from 155p * Biomerieux BIOX.PA : HSBC raises target price to EUR 126 from EUR 120 * Diasorin DIAS.MI : HSBC cuts to hold from buy * Givaudan SA GIVN.S : Citigroup cuts target price to CHF 4650 from CHF 4750 * Oxf
A
A
A
A
B
B
C
D
E
E
G
G
I
L
L
S
T
W
Q
A
A
A
D
U

Biomerieux Receives Marking For Vidas® Vitamin B12 Total

BRIEF-Biomerieux Receives CE-Marking For Vidas® Vitamin B12 Total Oct 15 (Reuters) - Biomerieux SA BIOX.PA : RECEIVES CE-MARKING FOR VIDAS® VITAMIN B12 TOTAL THE COMMERCIAL LAUNCH OF VIDAS® VITAMIN B12 TOTAL IS PLANNED IN SELECT COUNTRIES AT THE END OF 2024, WITH AN EXTENDED ROLLOUT IN Q1 2025 Source text shorturl.at/fD69y Further company covera
B

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.